Skip to main content
Institutional deep-dive - valuation, health, statements

Financial Analysis

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Fundamentals

MCKESSON CORP MCK

· Consumer · Wholesale-Drugs, Proprietaries & Druggists' Sundries

FY2026 10-K, filed 2026-05-08
SEC EDGAR

Filing evidence summary

Mixed evidenceCoverage 5/5 core metrics

Debt/equity is shown as not meaningful rather than as a negative leverage ratio.

Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.

Evidence signals

  • Shareholders' equity was non-positive

    Debt/equity is shown as not meaningful rather than as a negative leverage ratio.

    Why this surfaced

    Same-period reported shareholders' equity was zero or negative; review the balance sheet and capital structure. Period end 2026-03-31.

  • 3 filing risk checks flagged

    Flagged areas: Solvency & liquidity.

    Why this surfaced

    The full financial analysis shows each value, threshold, and sector limitation.

  • Operating margin was stable

    Operating margin changed +0.3 percentage points from the prior annual period.

    Why this surfaced

    Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2026-03-31.

  • Revenue expanded

    Latest reported annual revenue changed +12.4% from the prior reported annual observation.

    Why this surfaced

    Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2026-03-31.

  • Free cash flow was positive

    Latest reported free cash flow was $5.7B.

    Why this surfaced

    Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2026-03-31.

Core trend metrics

Latest annual revenue growth
+12.4%
as of 2026-03-31
Latest annual operating margin
1.5%
as of 2026-03-31
Free cash flow
$5.7B
as of 2026-03-31
Debt / equity
N/M
as of 2026-03-31
ROIC snapshot
93.4%
period varies

Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.

Where to look next

Risk checks

3of 11 rule-based checks flagged
  • Solvency & liquidity

Financial movement

  • Cash→ flat
  • Long-term debt→ flat
  • Inventory→ flat
  • Receivables→ flat
  • Current assets→ flat

Source & freshness

Source
SEC EDGAR XBRL
Fetched
2026-11-22
Latest period end
2026-03-31
Filings
EDGAR ↗

Reported segment mix

Not available for MCK: no dimensional revenue or operating-income facts for this filer in the ingested DERA files (segment, product/service, geography axes). Missing is not zero - a filer that reports one segment simply has no split to show.

Peer percentiles

latest fiscal year ending 2026-03-31 · among 4,026 US-listed filers · 477 in Consumer
MetricValuevs all filersvs sector
Revenue
latest fiscal-year revenue as filed
$403.4B
100thof 3,198
top third
100thof 459
top third
Revenue growth
latest fiscal-year revenue vs the prior fiscal year
12.4%
66thof 3,041
middle third
84thof 445
top third
Gross margin
gross profit ÷ revenue
3.6%
5thof 1,557
bottom third
3rdof 324
bottom third
Operating margin
operating income ÷ revenue
1.5%
46thof 2,733
middle third
35thof 431
middle third
Net margin
net income ÷ revenue
1.2%
45thof 3,157
middle third
40thof 455
middle third
Free-cash-flow margin
(operating cash flow − |capex|) ÷ revenue
1.4%
38thof 2,598
middle third
31stof 412
bottom third
Days sales outstanding
receivables ÷ revenue × 365 · lower is ranked higher
25 days
77thof 2,340
top third
48thof 380
middle third
Net debt ÷ operating cash flow
net debt ÷ operating cash flow (OCF > 0) · lower is ranked higher
0.4×
73rdof 1,501
top third
77thof 238
top third
Cash conversion
operating cash flow ÷ net income (net income > 0)
1.3×
40thof 2,222
middle third
33rdof 314
bottom third
Cash-flow accrual ratio
(net income − operating cash flow) ÷ average total assets · lower is ranked higher
-1.8%
30thof 3,803
bottom third
21stof 451
bottom third

Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.

Earnings quality

latest fiscal year ending 2026-03-31 · accruals and cash conversion as filed
Cash conversion
1.29×
operating cash flow ÷ net income, latest fiscal year
Cash-flow accrual ratio
-1.8%
(net income − operating cash flow) ÷ average total assets
Balance-sheet accrual ratio
-
change in net operating assets ÷ average net operating assets
Cash-backed years
5 of 5
fiscal years where operating cash flow met or exceeded net income
Mean cash conversion
2.00×
across the stored fiscal years with positive net income

Per fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.

Point-in-time ledger

first-reported vs latest filing · periods since 2020-01-01 · 3 changed periods
Line itemPeriodFirst reportedLatest filingChangeFilings
Share repurchases
PaymentsForRepurchaseOfCommonStock
quarter 2020-06-30$24M
10-Q 2020-08-03
$0
10-Q 2021-08-05
-100.0%first · latest
Share repurchases
PaymentsForRepurchaseOfCommonStock
fiscal year 2021-03-31$770M
10-K 2021-05-12
$742M
10-K 2023-05-09
-3.6%first · latest · 3 filings carry it
Share repurchases
PaymentsForRepurchaseOfCommonStock
fiscal year 2020-03-31$1.95B
10-K 2020-05-22
$1.93B
10-K 2022-05-09
-1.0%first · latest · 3 filings carry it

First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding; share counts re-presented by an integer split ratio are listed as split adjustments, not restatements. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.

Notes by disclosure type

debt, leases, revenue, segments, contingencies, taxes and more · the filer's own words
Latest quarterly report10-Q FY2026 Q3 · filed 20260204View filing
Commitments and contingencies · 17,287 characters as filed

"Commitments and Contingent Liabilities In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in Financial Note 17 to the Companys 2025, Annual Report , Financial Note 11 to the Companys 10-Q filing for the quarterly period ended June 30, 2025 , and Financial Note 11 to the Companys 10-Q filing for the quarterly period ended September 30, 2025 , which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations. Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of l …

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

Debt · 9,643 characters as filed

Debt and Financing Activities Long-term debt consisted of the following: (In millions) December 31, 2025 March 31, 2025 U.S. Dollar notes (1) (2) 0.90% Notes due December 3, 2025 $ $ 500 1.30% Notes due August 15, 2026 500 499 7.65% Debentures due March 1, 2027 150 150 3.95% Notes due February 16, 2028 343 343 4.90% Notes due July 15, 2028 400 399 4.75% Notes due May 30, 2029 196 196 4.25% Notes due September 15, 2029 500 500 4.65% Notes due May 30, 2030 650 4.95% Notes due May 30, 2032 650 5.10% Notes due July 15, 2033 597 597 5.25% Notes due May 30, 2035 699 6.00% Notes due March 1, 2041 218 217 4.88% Notes due March 15, 2044 255 255 Foreign currency notes (1) (3) 1.50% Euro Notes due November 17, 2025 649 1.63% Euro Notes due October 30, 2026 587 541 3.13% Sterling Notes due February 17, 2029 606 581 Lease and other obligations 206 227 Total debt 6,557 5,654 Less: Current portion 1,132 1,191 Total long-term debt $ 5,425 $ 4,463 (1) These notes are unsecured and unsubordinated obligations of the Company. (2) Interest on these U.S. dollar notes is payable semi-annually. (3) Interest on these foreign currency notes is payable annually. Long-Term Debt The Companys long-term debt includes both U.S. dollar and foreign currency-denominated borrowings. At December 31, 2025 and March 31, 2025, $6.6 billion and $5.7 billion, respectively, of total debt was outstanding, of which $1.1 billion and $1.2 billion, respectively, was included under the caption Current portion of long-term d …

DebtDisclosureTextBlock · excerpt; the full note is in the filing

Fair value · 7,370 characters as filed

Fair Value Measurements The Company measures certain assets and liabilities at fair value in accordance with ASC Topic 820, Fair Value Measurements and Disclosures . The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows: Level 1 - quoted prices in active markets for identical assets or liabilities. Level 2 - significant other observable market-based inputs. Level 3 - significant unobservable inputs for which little or no market data exists and requires considerable assumptions that are significant to the fair value measurement. Assets and Liabilities Measured at Fair Value on a Recurring Basis Cash and cash equivalents at December 31, 2025 and March 31, 2025 included the Companys investments in money market funds of $590 million and $1.0 billion, respectively, which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature. Fair values of the Companys interest rate swaps, cross-currency swaps, and foreign currency forward contracts were determined using observable inputs from available market information, including quoted interest rates, foreign currency exchange rates, and other observable inputs from available marke …

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

Goodwill and intangibles · 3,227 characters as filed

Goodwill and Intangible Assets, Net Goodwill In the second quarter of fiscal 2026, the Company implemented a new segment reporting structure which resulted in four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. These reportable segments encompass all operating segments of the Company. The Companys Norwegian operations are included in Other. The Company evaluates goodwill for impairment on an annual basis in the first fiscal quarter, and more frequently if indicators for potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit. The annual impairment testing performed in fiscal 2026 and fiscal 2025 did not indicate any impairment of goodwill. Changes in the carrying amount of goodwill were as follows: (In millions) North American Pharmaceutical Oncology & Multispecialty Prescription Technology Solutions Medical-Surgical Solutions Other (2) Total Balance, March 31, 2025 $ 2,737 $ 2,724 $ 2,027 $ 2,507 $ 27 $ 10,022 Goodwill acquired 1,266 39 1,305 Disposals (9) (28) (37) Foreign currency translation adjustments, net 63 1 64 Other adjustments (1) (30) (30) Balance, December 31, 2 …

GoodwillAndIntangibleAssetsDisclosureTextBlock · excerpt; the full note is in the filing

Income taxes · 2,567 characters as filed

Income Taxes Income tax expense was as follows: Three Months Ended December 31, Nine Months Ended December 31, (Dollars in millions) 2025 2024 2025 2024 Income tax expense $ 380 $ 298 $ 832 $ 669 Reported income tax rate 23.3 % 24.3 % 20.4 % 23.5 % Fluctuations in the Companys reported income tax rates were primarily due to changes in the mix of earnings among various taxing jurisdictions and discrete items recognized in the quarters. During the nine months ended December 31, 2025, the Company recognized a discrete tax benefit of $119 million related to the release of a valuation allowance in a foreign jurisdiction based on managements reassessment of the amount of its deferred tax assets that are more likely than not to be realized. As of each reporting date, the Company considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets and determined that there is sufficient positive evidence to conclude that it is more likely than not that these additional deferred tax assets will be realized and reduced the valuation allowance accordingly. During the three and nine months ended December 31, 2024, the Company recorded non-cash pre-tax charges of $23 million and $666 million respectively, to remeasure the Canadian retail disposal group to fair value less costs to sell, as described in Financial Note 2, Business Acquisitions and Divestitures. The Companys reported income tax rates for the three and nine months ende …

IncomeTaxDisclosureTextBlock · excerpt; the full note is in the filing

New accounting pronouncements · 2,734 characters as filed

Recently Adopted Accounting Pronouncements In the first quarter of fiscal 2026, the Company adopted Accounting Standards Update (ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosure s using a prospective transition method. ASU 2023-09 improves the transparency of income tax disclosures by requiring, on an annual basis, consistent categories, and greater disaggregation of information in the rate reconciliation as well as income taxes paid disaggregated by jurisdiction. While this accounting standard will increase disclosures related to the Companys income taxes within its Annual Report on Form 10-K for the year ended March 31, 2026, the standard did not have any impact on the Companys Consolidated Financial Statement results. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2024, the Financial Accounting Standards Board (FASB) issued ASU 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 requires disclosure of certain costs and expenses on an interim and annual basis in the notes to the financial statements. ASU 2024-03 is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, as clarified by ASU 2025-01, Income StatementReporting Comprehensive IncomeExpense Disaggregation Disclosures (Subtopic 220-40) . Early adoption i …

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

Restructuring · 7,422 characters as filed

"Restructuring, Impairment, and Related Charges, Net The Company recorded restructuring, impairment, and related charges, net of $36 million and $32 million for the three months ended December 31, 2025 and 2024, respectively, and $146 million and $276 million for the nine months ended December 31, 2025 and 2024, respectively. Of these charges $213 million was included in Restructuring, impairment, and related charges, net and $63 million was included in Cost of sales in the Condensed Consolidated Statement of Operations, for the nine months ended December 31, 2024. During the second quarter of fiscal 2025, the Company approved enterprise-wide initiatives to modernize and accelerate the technology service operating model which were intended to improve business continuity, compliance, operating efficiency and advance investments to streamline the organization. These initiatives include cost reduction efforts and support other rationalization efforts within Corporate, and the Medical-Surgical Solutions and North American Pharmaceutical segments to help realize long-term sustainable growth. The Company anticipates total charges related to these initiatives of $650 million to $700 million, consisting primarily of employee severance and other employee-related costs as well as facility, exit, and other related costs, including long-lived asset impairments. These programs are anticipated to be substantially complete in fiscal 2028. For the three and nine months ended December 31, 202 …

RestructuringAndRelatedActivitiesDisclosureTextBlock · excerpt; the full note is in the filing

Segment reporting · 13,144 characters as filed

Segments of Business Commencing in the second quarter of fiscal 2026, the Company implemented a new segment reporting structure which resulted in four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, RxTS, and M edical-Surgical Solutions. The Companys Norwegian operations have been classified as held for sale and are included in Other as the Norway disposal group. All prior segment information has been recast to reflect the Companys new segment structure and current period presentation. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments. These segment changes reflect how the Companys Chief Executive Officer, who is the chief operating decision maker (CODM), allocates resources and assesses performance beginning in the second quarter of fiscal 2026. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. The Company evaluates the performance of its operating segments on a number of measures, including revenues and operating profit before interest expense and income taxes. The CODM uses operating profit before interest expense and income taxes to assess performance and allocate resources for each reportable segment during the Companys annual long-term planning process and th …

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

Stockholders' equity · 10,862 characters as filed

Stockholders' Deficit Each share of the Companys outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to participate equally in any dividends declared by the Companys Board of Directors (the Board). On July 29, 2025, the Company raised its quarterly dividend from $0.71 to $0.82 per share of common stock. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements, legal requirements, and other factors. Share Repurchase Plans The Board has authorized the repurchase of common stock. The Company may repurchase common stock from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Companys stock price, corporate and regulatory requirements, tax implications, restrictions under the Companys debt obligations, other uses for capital, impacts on the value of remaining shares, cash generated from operations, and market and economic conditions. Excis …

StockholdersEquityNoteDisclosureTextBlock · excerpt; the full note is in the filing

Source: SEC DERA Financial Statement and Notes data sets (txt.tsv), excerpts of the filer's own note text; the full note is in the linked filing. Excerpts are the first part of each note exactly as tagged in the filing; open the filing for the full text and the tables. Descriptive and educational, not advice.

Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.